These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 14642604)

  • 21. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1.
    Maiorana A; Malamisura M; Emma F; Boenzi S; Di Ciommo VM; Dionisi-Vici C
    Mol Genet Metab; 2014 Nov; 113(3):188-93. PubMed ID: 25172236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
    van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
    Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice.
    Eggenhofer E; Doenecke A; Renner P; Slowik P; Piso P; Geissler EK; Schlitt HJ; Dahlke MH; Popp FC
    J Gastroenterol Hepatol; 2010 May; 25(5):1002-8. PubMed ID: 20546455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.
    Kurihara K; Toyoda H; Amoano K; Inoue M; Uchida K; Sakurai H; Hayashi A; Hirayama M
    Pediatr Int; 2018 Nov; 60(11):1039-1041. PubMed ID: 30375135
    [No Abstract]   [Full Text] [Related]  

  • 26. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
    Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
    J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G; Tanguay RM
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evolution of a case of tyrosinemia type I treated with NTBC].
    Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
    An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From Weed Killer to Wonder Drug.
    Lock EA
    Adv Exp Med Biol; 2017; 959():175-185. PubMed ID: 28755195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue from neonatal death in the murine model of hereditary tyrosinemia by glutathione monoethylester and vitamin C treatment.
    Langlois C; Jorquera R; Orejuela D; Bergeron A; Finegold MJ; Rhead WJ; Tanguay RM
    Mol Genet Metab; 2008 Mar; 93(3):306-13. PubMed ID: 18023223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo lentiviral vector gene therapy to cure hereditary tyrosinemia type 1 and prevent development of precancerous and cancerous lesions.
    Nicolas CT; VanLith CJ; Hickey RD; Du Z; Hillin LG; Guthman RM; Cao WJ; Haugo B; Lillegard A; Roy D; Bhagwate A; O'Brien D; Kocher JP; Kaiser RA; Russell SJ; Lillegard JB
    Nat Commun; 2022 Aug; 13(1):5012. PubMed ID: 36008405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hereditary Tyrosinemia Type 1 in Turkey.
    Aktuglu-Zeybek AC; Kiykim E; Cansever MS
    Adv Exp Med Biol; 2017; 959():157-172. PubMed ID: 28755194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
    Al-Dhalimy M; Overturf K; Finegold M; Grompe M
    Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
    Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
    Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetic tyrosinemias.
    Scott CR
    Am J Med Genet C Semin Med Genet; 2006 May; 142C(2):121-6. PubMed ID: 16602095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers.
    Hall MG; Wilks MF; Provan WM; Eksborg S; Lumholtz B
    Br J Clin Pharmacol; 2001 Aug; 52(2):169-77. PubMed ID: 11488774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
    Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
    Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells.
    Wu G; Liu N; Rittelmeyer I; Sharma AD; Sgodda M; Zaehres H; Bleidissel M; Greber B; Gentile L; Han DW; Rudolph C; Steinemann D; Schambach A; Ott M; Schöler HR; Cantz T
    PLoS Biol; 2011 Jul; 9(7):e1001099. PubMed ID: 21765802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.
    Ellis MK; Whitfield AC; Gowans LA; Auton TR; Provan WM; Lock EA; Smith LL
    Toxicol Appl Pharmacol; 1995 Jul; 133(1):12-9. PubMed ID: 7597701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTBC and Correction of Renal Dysfunction.
    Maiorana A; Dionisi-Vici C
    Adv Exp Med Biol; 2017; 959():93-100. PubMed ID: 28755187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.